Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISE CALF DVT Study: Rivaroxaban for Isolated Calf Deep Vein Thrombosis
jRCTs041190009Completed
- Sponsor
- Bayer
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of rivaroxaban in deep vein thrombosis (DVT) and venous thromboembolism (VTE) (2 arms), sponsored by Bayer. Primary endpoint: Composite VTE recurrence (primary). Started May 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)venous thromboembolism (VTE)
Beyond the preview
Go deeper on jRCTs041190009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190009.